When should antimicrobial therapy be started in NTM pulmonary disease? - Amsterdam 2025

Treatment decisions in non-tuberculous mycobacteria lung disease: when to start, when to (de)escalate and when to stop?

Chair(s): Natalie Lorent, Giovanni Fumagalli, Barbara Hoffmann

Session type: Symposium

When should antimicrobial therapy be started in NTM pulmonary disease?

Heinke Kunst

EVENTS HOME

Replay
Slides

Previous presentation

Next presentation

Session content

When should antimicrobial therapy be started in NTM pulmonary disease?

Heinke Kunst

Replay

Slides

The critical role of the host in NTM disease susceptibility and management

Kenneth N. Olivier

Replay

Slides

Monitoring Disease Progression and Treatment Response: Clinical Predictors and Biomarkers

Jea-joon Yim

Replay

Slides

Antimicrobial therapy for NTM lung disease: how long is long enough?

Raquel Duarte

Replay

Slides

Discussion and Q&A

Replay

Session aims

to look beyond the 2020 NTM management guidelines addressing common issues of when to start and stop antimicrobial therapy; to learn about the most recent advances in biomarker research for non-tuberculous mycobacteria (NTM) disease activity and treatment response, which can inform treatment decisions; to get the latest insights into the host immune response to NTM and possible translations to host-directed therapies.

CDN Connection Issue

The ERS Congress 2025, Amsterdam

#{title}